ERBB2 and breast carcinoma: In 2014, only 19% of patients with HER2-positive tumors received trastuzumab in both the public and private healthcare system despite it being considered an essential medicine by the World Health Organization (WHO) with an established clinical benefit in early breast cancer [75].